TEXAS CANCER GENETICS CONSORTIUM

描述：（申请人的描述）我们提出了一种德克萨斯癌症遗传学 TCGC联盟对癌症遗传学网络（CGN）RFA的回应 CA-97-004 该TCGC将为CGN带来基础知识方面的广泛专业知识 临床癌症遗传学、人类和分子遗传学、 保密的人类癌症遗传学数据，人类癌症的社区外展 遗传学、专业和公共教育，以及 癌症遗传咨询和检测的影响。 TCGC将包括 现有癌症高危临床人群，德系犹太人 人群，家族性乳腺癌、结肠癌、MEN 2、NF 1和其他 遗传易感性综合征，许多研究已经进行了几十年， 参与筛查和早期发现的癌症高危患者 研究或化学预防试验，以及癌症患者的大型数据库 从中识别高风险家庭成员，以进行潜在招募， CGN。 德克萨斯州的人口在种族构成上是多样化的，TCGC 包括在评估需求方面有良好记录的调查人员， 西班牙裔和非洲裔美国人社区在医疗保健方面， 对这些社区及其医疗保健提供者进行健康教育，并在 招募他们参与家族性癌症登记和临床 和研究。 这项申请的资助将提供 TCGC有机会加强我们在联合体内部的互动， 为CGN的设计贡献我们的研究经验和专业知识， 实施，并利用我们在招聘方面的经验和专业知识 CGN方案的高风险患者。 长期目标是为 癌症易感基因的识别，其机制， 动作、频率、频率和遗传或环境风险调节因子， 将这些信息整合到最佳的患者管理中，并评估 需要和提供教育，以解决道德和心理社会问题 人类癌症遗传学。

DESCRIPTION: (Applicant's Description) We propose a Texas Cancer Genetics Consortium (TCGC) in response to the Cancer Genetics Network (CGN) RFA CA-97-004. This TCGC would bring to the CGN extensive expertise in basic and clinical cancer genetics, human and molecular genetics, management of confidential human cancer genetics data, community outreach in human genetics, professional and public education, and psychosocial studies of the impact of cancer genetic counseling and testing. The TCGC will include existing cancer high risk clinical populations, Ashkenazi Jewish populations, registries of familial breast, colon, MEN2, NF1 and other genetic susceptibility syndromes, many followed in studies for decades, patients at high cancer risk participating in screening and early detection studies or chemoprevention trials, and a large database of cancer patients from which to identify high risk family members for potential recruitment to the CGN. The Texas population is diverse in ethnic makeup, and the TCGC includes investigators with proven track records in assessing needs of the Hispanic and African American communities in health care, in providing health education to those communities and their healthcare providers, and in recruiting their participation in familial cancer registries and clinical and research studies. Funding of this application would provide the opportunity for our TCGC to strengthen our within consortium interactions, to contribute our research experience and expertise to the CGN design and implementation, and to utilize our experience and expertise in recruitment of high risk patients to CGN protocols. The long term goal is to contribute to the identification of cancer susceptibility genes, their mechanisms of action, frequency, penetrance, and genetic or environmental risk modifiers, to integrate this information into optimal patient management, and to assess needs and provide education to address the ethical and psychosocial concerns surrounding human cancer genetics.